| SKIP001136 | |
| SKIP ID | SKIP001136 |
| Organism(En) | - |
| Organism(Ja) | - |
| Cell Type(En) | - |
| Cell Type(Ja) | - |
| Cell Tissue(En) | - |
| Cell Tissue(Ja) | - |
| Cell Origin | Diseased |
| Cell Name 1(En) | ATCC-DYS0530 |
| Cell Name 1(Ja) | ATCC-DYS0530 |
| Cell Name 2(En) | - |
| Cell Name 2(Ja) | - |
| Disease Name 1(Ja) | パーキンソン病 |
| ICD Code 1 | G20 |
| Disease Name 1(En) | Parkinson's disease |
| OMIM1 | 605543 |
| Disease Name 2(Ja) | 喘息 |
| ICD Code 2 | J45 |
| Disease Name 2(En) | Asthma |
| OMIM 2 | 600807 |
| Disease Name 3(Ja) | うつ病 |
| ICD Code 3 | F209 |
| Disease Name 3(En) | Depression |
| OMIM 3 | 181500 |
| Age | 63 |
| Age Range | 60-69 |
| Sex | Male |
| Race(En) | - |
| Race(Ja) | - |
| Genetic Diagnosis | No |
| Not Detected | No |
| Description(En) | Disease iPS cell lines derived from patient with Parkinson disease, asthma, depression |
| Description(Ja) | 疾患由来iPS細胞株（パーキンソン病、喘息、うつ病） |
| Cell Morphology | human ES-like |
| Grade | Research Grade |
| Vector | Sendai virus |
| Transgene | OCT3/4,SOX2,KLF4,and MYC |
| Adhesiveness | - |
| Feeder | -- |
| Feeder Cell | - |
| Medium | Pluripotent Stem Cell SFM XF/FF |
| Genome Editing | - |
| CO2 | 5% |
| Mycoplasma | - |
| Detection of Contaminants Mycoplasma | - |
| Pluripotent Markers | - |
| Pluripotent Markers Assay | - |
| in vitro Differentiation | - |
| in vitro Differentiation Assay | - |
| in vivo Differentiation | - |
| in vivo Differentiation Assay | - |
| Other 1 Assay | - |
| Other 1 Assay Method | - |
| Other 2 Assay | - |
| Other 2 Assay Method | - |
| Other 3 Assay | - |
| Other 3 Assay Method | - |
| Karyotype | - |
| Karyotype Assay | - |
| Remaining Vector Detection | - |
| Remaining Vector Detection Assay | - |
| STR | Yes |
| HLA | - |
| Stem Cell Transcriptome analysis | - |
| Stem Cell Transcriptome analysis Assay | - |
| Author Name(En) | Summit Pharmaceuticals Intl. |
| Author Name(Ja) | 住商ファーマインターナショナル株式会社 |
| Author Organization(En) | Summit Pharmaceuticals Intl. |
| Author Organization(Ja) | 住商ファーマインターナショナル株式会社 |
| Author Contact Email | atcc[at]summitpharma[dot]co[dot]jp |
| PI Organization(En) | American Type Culture Collection (ATCC) |
| PI Organization(Ja) | American Type Culture Collection (ATCC) |
| PI Name(En) | American Type Culture Collection (ATCC) |
| PI Name(Ja) | American Type Culture Collection (ATCC) |
| PI Contact Email | Tech[at]atcc[dot]org |
| Availability | Available |
| Provider Organization(En) | Summit Pharmaceuticals Intl. Corp. |
| Provider Organization(Ja) | 住商ファーマインターナショナル株式会社 |
| Provider Email | atcc[at]summitpharma[dot]co[dot]jp |
| Provider URL | https://www.atcc.org/Products/All.aspx |
| Ethical Statement(En) | - |
| Ethical Statement(Ja) | - |
| Terms of Use(En) | - |
| Terms of Use(Ja) | - |
| PubMed ID | - |
| DOI | - |
| Title | - |
| Authors | - |
| Journal | - |
| Year | - |
| Volume | - |
| Issue | - |
| Pages | - |
| URL | - |
| Free input | - |
| Note | ATCC iPSCs have been adapted to feeder- and serum-free culture conditions. |